|
1
|
Balch CM, Soong SJ, Gershenwald JE,
Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross
MI, Kirkwood JM, et al: Prognostic factors analysis of 17,600
melanoma patients: Validation of the American Joint Committee on
Cancer melanoma staging system. J Clin Oncol. 19:3622–3634.
2001.PubMed/NCBI
|
|
2
|
Cummins DL, Cummins JM, Pantle H,
Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant
melanoma. Mayo Clin Proc. 81:500–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Culos KA and Cuellar S: Novel targets in
the treatment of advanced melanoma: New first-line treatment
options. Ann Pharmacother. 47:519–526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma C and Armstrong AW: Severe adverse
events from the treatment of advanced melanoma: A systematic review
of severe side effects associated with ipilimumab, vemurafenib,
interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog
Treat. 25:401–408. 2014. View Article : Google Scholar
|
|
5
|
Kuphal S, Bauer R and Bosserhoff AK:
Integrin signaling in malignant melanoma. Cancer Metastasis Rev.
24:195–222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marshall JF, Rutherford DC, Happerfield L,
Hanby A, McCartney AC, Newton-Bishop J and Hart IR: Comparative
analysis of integrins in vitro and in vivo in uveal and cutaneous
melanomas. Br J Cancer. 77:522–529. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nip J and Brodt P: The role of the
integrin vitronectin receptor, alpha v beta 3 in melanoma
metastasis. Cancer Metastasis Rev. 14:241–252. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson JP: Cell adhesion molecules in the
development and progression of malignant melanoma. Cancer
Metastasis Rev. 18:345–357. 1999. View Article : Google Scholar
|
|
9
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar
|
|
10
|
Jin H and Varner J: Integrins: Roles in
cancer development and as treatment targets. Br J Cancer.
90:561–565. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petitclerc E, Strömblad S, von Schalscha
TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA and Brooks PC:
Integrin αvβ3 promotes M21 melanoma growth in
human skin by regulating tumor cell survival. Cancer Res.
59:2724–2730. 1999.PubMed/NCBI
|
|
12
|
Smith SD, Enge M, Bao W, Thullberg M,
Costa TD, Olofsson H, Gashi B, Selivanova G and Strömblad S:
Protein kinase Cα (PKCα) regulates p53 localization and melanoma
cell survival downstream of integrin αv in three-dimensional
collagen and in vivo. J Biol Chem. 287:29336–29347. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao W and Strömblad S: Integrin
alphav-mediated inactivation of p53 controls a MEK1-dependent
melanoma cell survival pathway in three-dimensional collagen. J
Cell Biol. 167:745–756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horton MA: The alpha v beta 3 integrin
‘vitronectin receptor’. Int J Biochem Cell Biol. 29:721–725. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eble: Integrin-Ligand Interaction. R.G.
Landes Company; Georgetown: 1997
|
|
16
|
Hsu MY, Shih DT, Meier FE, Van Belle P,
Hsu JY, Elder DE, Buck CA and Herlyn M: Adenoviral gene transfer of
beta3 integrin subunit induces conversion from radial to vertical
growth phase in primary human melanoma. Am J Pathol. 153:1435–1442.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trikha M, Zhou Z, Timar J, Raso E, Kennel
M, Emmell E and Nakada MT: Multiple roles for platelet GPIIb/IIIa
and alphavbeta3 integrins in tumor growth, angiogenesis, and
metastasis. Cancer Res. 62:2824–2833. 2002.PubMed/NCBI
|
|
18
|
Oliva IB, Coelho RM, Barcellos GG,
Saldanha-Gama R, Wermelinger LS, Marcinkiewicz C, Benedeta Zingali
R and Barja-Fidalgo C: Effect of RGD-disintegrins on melanoma cell
growth and metastasis: Involvement of the actin cytoskeleton, FAK
and c-Fos. Toxicon. 50:1053–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang IC, Kim DS, Jang Y and Chung KH:
Suppressive mechanism of salmosin, a novel disintegrin in B16
melanoma cell metastasis. Biochem Biophys Res Commun. 275:169–173.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hutchinson JH, Halczenko W, Brashear KM,
Breslin MJ, Coleman PJ, Duong T, Fernandez-Metzler C, Gentile MA,
Fisher JE, Hartman GD, et al: Nonpeptide alphavbeta3 antagonists.
8. In vitro and in vivo evaluation of a potent alphavbeta3
antagonist for the prevention and treatment of osteoporosis. J Med
Chem. 46:4790–4798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murphy MG, Cerchio K, Stoch SA,
Gottesdiener K, Wu M and Recker R; L-000845704 Study Group: Effect
of L-000845704, an alphaVbeta3 integrin antagonist, on markers of
bone turnover and bone mineral density in postmenopausal
osteoporotic women. J Clin Endocrinol Metab. 90:2022–2028. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosenthal MA, Davidson P, Rolland F,
Campone M, Xue L, Han TH, Mehta A, Berd Y, He W and Lombardi A:
Evaluation of the safety, pharmacokinetics and treatment effects of
an αvβ3 integrin inhibitor on bone turnover
and disease activity in men with hormone-refractory prostate cancer
and bone metastases. Asia Pac J Clin Oncol. 6:42–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Simon KO, Nutt EM, Abraham DG, Rodan GA
and Duong LT: The alphavbeta3 integrin regulates
alpha5beta1-mediated cell migration toward fibronectin. J Biol
Chem. 272:29380–29389. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abraham DG, Nutt EM, Bednar RA, Bednar B,
Gould RJ and Duong LT: Arginine-glycine-aspartic acid mimics can
identify a transitional activation state of recombinant alphaIIb
beta3 in human embryonic kidney 293 cells. Mol Pharmacol.
52:227–236. 1997.PubMed/NCBI
|
|
25
|
Kossodo S, Pickarski M, Lin SA, Gleason A,
Gaspar R, Buono C, Ho G, Blusztajn A, Cuneo G, Zhang J, et al: Dual
in vivo quantification of integrin-targeted and protease-activated
agents in cancer using fluorescence molecular tomography (FMT). Mol
Imaging Biol. 12:488–499. 2010. View Article : Google Scholar
|
|
26
|
Pickarski M, Hayami T, Zhuo Y and Duong T:
Molecular changes in articular cartilage and subchondral bone in
the rat anterior cruciate ligament transection and meniscectomized
models of osteoarthritis. BMC Musculoskelet Disord. 12:1972011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fidler IJ: Biological behavior of
malignant melanoma cells correlated to their survival in vivo.
Cancer Res. 35:218–224. 1975.PubMed/NCBI
|
|
28
|
Fidler IJ and Kripke ML: Metastasis
results from preexisting variant cells within a malignant tumor.
Science. 197:893–895. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cowden Dahl KD, Robertson SE, Weaver VM
and Simon MC: Hypoxia-inducible factor regulates alphavbeta3
integrin cell surface expression. Mol Biol Cell. 16:1901–1912.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barczyk M, Carracedo S and Gullberg D:
Integrins. Cell Tissue Res. 339:269–280. 2010. View Article : Google Scholar
|
|
31
|
Giancotti FG and Ruoslahti E: Integrin
signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Belle PA, Elenitsas R, Satyamoorthy K,
Wolfe JT, Guerry D IV, Schuchter L, Van Belle TJ, Albelda S, Tahin
P, Herlyn M, et al: Progression-related expression of beta3
integrin in melanomas and nevi. Hum Pathol. 30:562–567. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Albelda SM, Mette SA, Elder DE, Stewart R,
Damjanovich L, Herlyn M and Buck CA: Integrin distribution in
malignant melanoma: Association of the beta 3 subunit with tumor
progression. Cancer Res. 50:6757–6764. 1990.PubMed/NCBI
|
|
34
|
Brooks PC: Role of integrins in
angiogenesis. Eur J Cancer. 32A:2423–2429. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brooks PC, Strömblad S, Sanders LC, von
Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and
Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the
surface of invasive cells by interaction with integrin alpha v beta
3. Cell. 85:683–693. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Danen EHJ: Integrin signaling as a cancer
drug target. ISRN Cell Biol. 2013:1351642013.http://dx.doi.org/10.1155/2013/135164.
Accessed: Jan 10, 2015. View Article : Google Scholar
|
|
37
|
Reardon DA, Fink KL, Mikkelsen T,
Cloughesy TF, O’Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ,
Rich KM, et al: Randomized phase II study of cilengitide, an
integrin-targeting arginine-glycine-aspartic acid peptide, in
recurrent glioblastoma multiforme. J Clin Oncol. 26:5610–5617.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim KB, Prieto V, Joseph RW, Diwan AH,
Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS,
et al: A randomized phase II study of cilengitide (EMD 121974) in
patients with metastatic melanoma. Melanoma Res. 22:294–301. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gutheil JC, Campbell TN, Pierce PR,
Watkins JD, Huse WD, Bodkin DJ and Cheresh DA: Targeted
antiangiogenic therapy for cancer using Vitaxin: A humanized
monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res.
6:3056–3061. 2000.PubMed/NCBI
|
|
40
|
Mcneel DG, Eickhoff J, Lee FT, King DM,
Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J,
et al: Phase I trial of a monoclonal antibody specific for
alphavbeta3 integrin (MEDI-522) in patients with advanced
malignancies, including an assessment of effect on tumor perfusion.
Clin Cancer Res. 11:7851–7860. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hersey P, Sosman J, O’Day S, Richards J,
Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M,
et al: Etaracizumab Melanoma Study Group: A randomized phase 2
study of etaracizumab, a monoclonal antibody against integrin
αvβ3, ± dacarbazine in patients with stage IV
metastatic melanoma. Cancer. 116:1526–1534. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Reynolds AR, Hart IR, Watson AR, Welti JC,
Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones
MC, et al: Stimulation of tumor growth and angiogenesis by low
concentrations of RGD-mimetic integrin inhibitors. Nat Med.
15:392–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Girotti MR, Saturno G, Lorigan P and
Marais R: No longer an untreatable disease: How targeted and
immunotherapies have changed the management of melanoma patients.
Mol Oncol. 8:1140–1158. 2014. View Article : Google Scholar : PubMed/NCBI
|
